The endocannabinoid-boosting compound URB597 prevented anxiety and depression behaviors in mice undergoing methamphetamine withdrawal, acting through CB1, CB2, and vanilloid receptor pathways.
Addiction pharmacology researchers, stimulant withdrawal treatment developers
URB597 prevented both anxiety and depression in meth-withdrawn mice
What the researchers found
Methamphetamine (30 mg/kg) caused anxiety and depression behaviors 3 days after withdrawal. URB597 (an endocannabinoid-enhancing compound) at 5-10 ng prevented these emotional deficits. The effect was blocked by CB1 antagonist AM251 and CB2 antagonist AM630, confirming involvement of both cannabinoid receptors. TRPV1 antagonist capsazepine showed dose-dependent effects: low doses blocked and high doses potentiated URB597's antidepressant action.
Why it matters
Methamphetamine withdrawal causes severe anxiety and depression that drive relapse. Identifying the endocannabinoid system as a treatment target could provide new pharmacological approaches for managing stimulant withdrawal symptoms.
The numbers in context
Methamphetamine 30 mg/kg induced symptoms at 3 days; URB597 effective at 5-10 ng/mouse; CB1 antagonist AM251 (1 ug) blocked antidepressant effect; CB2 antagonist AM630 (5-10 ug) suppressed antidepressant activity; capsazepine showed dose-dependent bidirectional effects
How the study worked
Male NMRI mice received methamphetamine (30 mg/kg) and were tested 3 days later in elevated plus maze (anxiety) and forced swim test (depression). URB597 was administered intracerebroventricularly 10 minutes before testing. Receptor involvement was probed using specific antagonists for CB1, CB2, and TRPV1.
What this study cannot tell us
Male mice only. Intracerebroventricular administration is not a clinically practical delivery route. Forced swim and elevated plus maze are simplified models of human depression and anxiety. Three-day withdrawal window may not capture the full timeline of human methamphetamine withdrawal.
How to read the evidence
Mechanistic animal study with systematic receptor probing, but limited by male-only design and non-translatable drug delivery route.
When this study was published
Published in 2021.
The bigger picture
The involvement of multiple receptor types (CB1, CB2, TRPV1) in mediating the anti-withdrawal effects suggests the endocannabinoid system offers multiple therapeutic entry points for treating stimulant withdrawal, rather than a single target.
Questions still open
- Would systemically administered endocannabinoid modulators show similar effects? Do these findings extend to female subjects and to other stimulant withdrawal (cocaine, amphetamine)?
Common questions
What is URB597?
How is this relevant to cannabis?
Read the original research
URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels.
Journal of psychopharmacology (Oxford, England), 35(7), 875-884
Citation
Ebrahimi-Ghiri, Mohaddeseh; Khakpai, Fatemeh; Zarrindast, Mohammad-Reza. (2021). URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels.. Journal of psychopharmacology (Oxford, England), 35(7), 875-884. https://doi.org/10.1177/0269881120965934
Explore the wider topic
- Weed Withdrawal Anxiety in Public: When Leaving the House Feels Impossible
- The DARE Response to Anxiety for Cannabis Withdrawal
- The Cannabis Withdrawal Anxiety Toolkit: Quick Techniques That Work
- Why Anxiety Gets Worse Before It Gets Better After Quitting Weed
- Breathing Exercises for Weed Withdrawal Anxiety
- Cannabis-Induced Anxiety: When Weed Stops Being Fun
- Does Weed Help or Hurt Anxiety? What Research Actually Shows
- Grounding Techniques for Cannabis Withdrawal: A Practical Toolkit
- Quitting Weed with Health Anxiety: Why Every Symptom Feels Like a Crisis
- How to Manage Anxiety Without Weed: 15 Evidence-Based Alternatives
- Quitting Weed with Anxiety Disorder: A Careful Approach
- Quitting Weed When You're on Anxiety Medication: What to Know
- Self-Medicating Anxiety with Weed: Why It Works Until It Doesn't
- Do I Need Therapy to Quit Weed? When Professional Help Makes Sense
- Weed and Anxiety: The Paradox That Traps People
- The Biphasic Effect: Low-Dose Calms, High-Dose Panics
- Weed and Generalized Anxiety Disorder (GAD): Why It Backfires
- Weed and Panic Attacks: The Connection Nobody Talks About
- Weed and Paranoia: When Cannabis Turns Your Mind Against You
- Weed and Social Anxiety: Why It Feels Like the Only Thing That Helps
- Why Weed Stopped Working for Your Anxiety
- Weed Withdrawal Anxiety: Understanding the Panic and How to Cope
- Weed Withdrawal Panic Attacks at Night: Why They Happen and How to Get Through Them
- Going Back to Work During Weed Withdrawal: Managing Anxiety and Staying Functional
- Withdrawal Anxiety vs Pre-Existing Anxiety: How to Tell the Difference